Design Therapeutics, Inc.
DSGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $349 | $148 | $572 | $984 |
| - Cash | $23 | $21 | $27 | $299 |
| + Debt | $2 | $3 | $4 | $4 |
| Enterprise Value | $329 | $130 | $549 | $689 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$1 | -$1 | -$0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$49 | -$66 | -$63 | -$36 |
| % Margin | – | – | – | – |
| Net Income | -$50 | -$67 | -$63 | -$36 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.88 | -1.19 | -1.14 | -0.77 |
| % Growth | 26.1% | -4.4% | -48.1% | – |
| Operating Cash Flow | -$43 | -$59 | -$51 | -$29 |
| Capital Expenditures | -$0 | -$0 | -$1 | -$2 |
| Free Cash Flow | -$43 | -$59 | -$52 | -$31 |